{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:37Z","timestamp":1772166097731,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether acute respiratory failure in patients with interstitial lung disease is reversible remains uncertain. Consequently, indications for extracorporeal membrane oxygenation in these patients are still controversial, except as a bridge to lung transplantation. The objective of this study was to clarify in-hospital mortality and prognostic factors in interstitial lung disease patients undergoing extracorporeal membrane oxygenation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this case\u2013control study using the Japanese Diagnosis Procedure Combination database, hospitalized interstitial lung disease patients receiving invasive mechanical ventilation and extracorporeal membrane oxygenation from 2010 to 2017 were reviewed. Patients\u2019 characteristics and treatment regimens were compared between survivors and non-survivors to identify prognostic factors. To avoid selection biases, patients treated with extracorporeal membrane oxygenation as a bridge to lung transplantation were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 164 interstitial lung disease patients receiving extracorporeal membrane oxygenation were included. Their in-hospital mortality was 74.4% (122\/164). Compared with survivors, non-survivors were older and received high-dose cyclophosphamide, protease inhibitors, and antifungal drugs more frequently, but macrolides and anti-influenza drugs less frequently. On multivariate analysis, the following factors were associated with in-hospital mortality: advanced age (odds ratio [OR] 1.043; 95% confidence interval [CI] 1.009\u20131.078), non-use of macrolides (OR 0.305; 95% CI 0.134\u20130.698), and use of antifungal drugs (OR 2.416; 95% CI 1.025\u20135.696).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately three-quarters of interstitial lung disease patients undergoing extracorporeal membrane oxygenation died in hospital. Moreover, advanced age, non-use of macrolides, and use of antifungal drugs were found to correlate with a poor prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-021-01805-w","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T15:04:01Z","timestamp":1627139041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of extracorporeal membrane oxygenation for acute respiratory failure with interstitial lung disease: a case control nationwide dataset study in Japan"],"prefix":"10.1186","volume":"22","author":[{"given":"Yuko","family":"Usagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Yamasue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"1805_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtcvs.2013.06.039","volume":"147","author":"S Gaudry","year":"2014","unstructured":"Gaudry S, Vincent F, Rabbat A, Nunes H, Crestani B, Naccache JM, Wolff M, Thabut G, Valeyre D, Cohen Y, Mal H. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg. 2014;147:47\u201353.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1805_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0061-2018","volume":"27","author":"JA Huapaya","year":"2018","unstructured":"Huapaya JA, Wilfong EM, Harden CT, Brower RG, Danoff SK. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27:1.","journal-title":"Eur Respir Rev"},{"key":"1805_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.chest.2018.01.006","volume":"153","author":"WD Gannon","year":"2018","unstructured":"Gannon WD, Lederer DJ, Biscotti M, Javaid A, Patel NM, Brodie D, Bacchetta M, Baldwin MR. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease. Chest. 2018;153:1387\u201395.","journal-title":"Chest"},{"key":"1805_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.chest.2017.06.016","volume":"152","author":"D Abrams","year":"2017","unstructured":"Abrams D, Brodie D. Extracorporeal membrane oxygenation for adult respiratory failure: 2017 update. Chest. 2017;152:639\u201349.","journal-title":"Chest"},{"key":"1805_CR5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2009.1535","volume":"302","author":"A Davies","year":"2009","unstructured":"Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, Forrest P, Gattas D, Granger E, Herkes R, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302:1888\u201395.","journal-title":"JAMA"},{"key":"1805_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(09)61069-2","volume":"374","author":"GJ Peek","year":"2009","unstructured":"Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351\u201363.","journal-title":"Lancet"},{"key":"1805_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12890-018-0643-3","volume":"18","author":"P Faverio","year":"2018","unstructured":"Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, Ora J, Rogliani P, Pellegrino G, Sferrazza Papa GF, et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm Med. 2018;18:70.","journal-title":"BMC Pulm Med"},{"key":"1805_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1164\/rccm.201508-1701OC","volume":"193","author":"FC Trudzinski","year":"2016","unstructured":"Trudzinski FC, Kaestner F, Sch\u00e4fers HJ, F\u00e4hndrich S, Seiler F, B\u00f6hmer P, Linn O, Kaiser R, Haake H, Langer F, et al. Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med. 2016;193:527\u201333.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2020","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of Diagnosis Procedure Combination (DPC): development of real data collection system for acute inpatient care in Japan. J Epidemiol. 2020;31(1):1\u20131.","journal-title":"J Epidemiol"},{"key":"1805_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","volume":"27","author":"H Yamana","year":"2017","unstructured":"Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476\u201382.","journal-title":"J Epidemiol"},{"key":"1805_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1164\/rccm.201311-2023OC","volume":"189","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, Scheinkestel C, Cooper DJ, Brodie D, Pellegrino V, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med. 2014;189:1374\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"1805_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1007\/s00134-013-3037-2","volume":"39","author":"M Schmidt","year":"2013","unstructured":"Schmidt M, Zogheib E, Roz\u00e9 H, Repesse X, Lebreton G, Luyt CE, Trouillet JL, Br\u00e9chot N, Nieszkowska A, Dupont H, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med. 2013;39:1704\u201313.","journal-title":"Intensive Care Med"},{"key":"1805_CR13","unstructured":"Extracorporeal Life Support Organization (ELSO) Guidelines for Adult Respiratory Failure August, 2017. http:\/\/www.elso.org."},{"key":"1805_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MAT.0000000000001193","volume":"66","author":"K Shekar","year":"2020","unstructured":"Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, Zakhary B, Ramanathan K, Starr J, Akkanti B, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. Asaio J. 2020;66:707\u201321.","journal-title":"Asaio J"},{"key":"1805_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","volume":"9","author":"P Zimmermann","year":"2018","unstructured":"Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.","journal-title":"Front Immunol"},{"key":"1805_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1378\/chest.10-0196","volume":"138","author":"AL Friedlander","year":"2010","unstructured":"Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;138:1202\u201312.","journal-title":"Chest"},{"key":"1805_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","volume":"23","author":"S Kanoh","year":"2010","unstructured":"Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590\u2013615.","journal-title":"Clin Microbiol Rev"},{"key":"1805_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"WI Sligl","year":"2014","unstructured":"Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42:420\u201332.","journal-title":"Crit Care Med"},{"key":"1805_CR19","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"1805_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12890-017-0437-z","volume":"17","author":"K Kawamura","year":"2017","unstructured":"Kawamura K, Ichikado K, Yasuda Y, Anan K, Suga M. Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study. BMC Pulm Med. 2017;17:94.","journal-title":"BMC Pulm Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01805-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T15:04:04Z","timestamp":1627139044000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01805-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01805-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-152666\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-152666\/v2","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"27 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional ethics committee of Oita University (approval no. 1613; approval date: May 20, 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participate"}},{"value":"Since all patient data were obtained in an anonymous manner, the requirement for individual informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have stated that there are no competing interests in connection with this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}